伊立替康在小细胞肺癌化疗中所致重度不良反应的相关因素分析  

Analysis of Related Factors of Severe Adverse Reactions Induced by Irinotecan in Small Cell Lung Cancer Chemotherapy

作　　者：张亮[1] 周秋云[1] 张宇[2] 王洁[1] 丁红梓[1] ZHANG Liang;ZHOU Qiuyun;ZHANG Yu;WANG Jie;DING Hongzi(Department of Pharmacy,Nanjing Chest Hospital,School of Medicine,Southeast University,Nanjing 210029,China;Department of Respiratory,Nanjing Chest Hospital,School of Medicine,Southeast University,Nanjing 210029,China)

机构地区：[1]东南大学医学院附属南京胸科医院药学部,南京210029 [2]东南大学医学院附属南京胸科医院呼吸内科,南京210029

出　　处：《药学与临床研究》2019年第5期332-336,共5页Pharmaceutical and Clinical Research

基　　金：江苏省药学会-奥赛康医院药学基金（A2017013）;南京市药学会-常州四药医院药学基金（2016YX015）

摘　　要：目的:分析小细胞肺癌患者使用伊立替康发生Ⅲ度以上不良反应的相关因素。方法:对2015年12月~2018年11月共91例使用伊立替康的小细胞肺癌患者进行回顾性分析,探讨影响Ⅲ度以上不良反应的危险因素。结果:有放疗史和既往接受化疗次数是导致Ⅲ度以上中性粒细胞减少、腹泻和呕吐的危险因素。结论:这类患者需密切关注,加强观察,注意病情变化。Objective: To analyze the related factors of above degree Ⅲ serious adverse reactions during the chemotherapy in patients with small cell lung cancer (SCLC) who received irinotecan. Methods: A retrospective analysis was performed on a total of 91 patients with SCLC who received irinotecan between December 2015 and November 2018, to explore the main factors affecting the occurrence of adverse reactions above grade Ⅲ. Results: The history of radiotherapy and frequency of chemotherapy were risk factors for neutropenia, diarrhea and vomit above grade Ⅲ. Conclusion: Patients with risk factors need close attention for changes of their conditions.

关 键 词：肺癌 伊立替康 严重不良反应 

分 类 号：R969.3[医药卫生—药理学]